01:51 AM EDT, 08/26/2026 (MT Newswires) -- Circio Holding (CRNA.OL) entered into a research partnership with fellow biotechnology company Full Circles Therapeutics. Under the agreement, the entities will combine their immune-silent C4DNATM vector platform and circVec platform to develop re-dosable non-viral gene treatments, according to a Wednesday release. The collaboration will see Full Circles Therapeutics design and produce the C4DNATM vectors, which have circVec inserts, while Circio will review the vectors' performance, expression, delivery, and immunogenicity.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.